No annual revenue total was found in Raphael Pharmaceutical Inc.'s SEC filings.
Raphael Pharmaceutical Inc. (RAPH) files with the SEC under industry code 2833, Medicinal Chemicals & Botanical Products.
Revenue
—
Net income (TTM)
$-980,000
+33.4% vs year-ago TTM
Operating cash flow (TTM)
$-15,000
+96.1% vs year-ago TTM
Free cash flow
$-761,000
EPS (TTM)
$-0.05
+36.5% vs year-ago TTM
Dividend per share
None
Shares outstanding
20.18M
+2.8% vs prior year
Net cash
$-22,000
FY 2024
Operating margin
—
Company profile
- Industry
- Medicinal Chemicals & Botanical Products (SIC 2833)
- Listed as
- RAPH (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- NV
- Headquarters
- Las Vegas, NV
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1415397
- Former names
- Easy Energy Inc (until May 14, 2021)
Other Medicinal Chemicals & Botanical Products companies
- Definium Therapeutics, Inc. DFTX
- Regencell Bioscience Holdings Ltd RGC
- Curaleaf Holdings, Inc. CURLF
- Trulieve Cannabis Corp. TRLV
- Cronos Group Inc. CRON
- TFA Therapeutics, Inc. RAJAF
- Tilray Brands, Inc. TLRY
- SNDL Inc. SNDL
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$1.2M | -$1.5M | -$1.3M | -$3.3M | -$1.6M |
| Net income | -$1.3M | -$1.5M | -$1.3M | -$3.4M | -$1.6M |
| Diluted EPS | $0.07 | $0.08 | $0.08 | $0.23 | — |
| Operating cash flow | -$210,000 | -$532,000 | -$1.2M | -$759,000 | -$1.4M |
| Free cash flow | — | — | — | -$761,000 | — |
| Total assets | $53,000 | $27,000 | $239,000 | $333,000 | $422,000 |
| Stockholders' equity | -$1.4M | -$742,000 | $107,000 | $106,000 | $128,000 |
| Cash and investments | $45,000 | $19,000 | $230,000 | — | $153,000 |
| Total debt | — | $41,000 | — | — | — |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement
|
Sep 1, 2026 | Jul 30, 2026 |
| 10-Q | Quarterly report | Aug 14, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Officer or director change
|
Jul 17, 2026 | Jul 16, 2026 |
| 10-Q | Quarterly report | May 14, 2026 | Mar 31, 2026 |
| 10-K | Annual report | Mar 31, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Officer or director change
|
Mar 24, 2026 | Dec 31, 2025 |
All 179 Raphael Pharmaceutical Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.